Article Versions Notes

Dubois F, Keller M, Hoflack J, Maille E, Antoine M, Westeel V, Bergot E, Quoix E, Lavolé A, Bigay-Game L, et al. Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial. Cancers. 2019; 11(12):1835. https://doi.org/10.3390/cancers11121835

Dubois, Fatéméh, Maureen Keller, Julien Hoflack, Elodie Maille, Martine Antoine, Virginie Westeel, Emmanuel Bergot, Elisabeth Quoix, Armelle Lavolé, Laurence Bigay-Game, and et al. 2019. "Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial" Cancers 11, no. 12: 1835. https://doi.org/10.3390/cancers11121835

Dubois, F., Keller, M., Hoflack, J., Maille, E., Antoine, M., Westeel, V., Bergot, E., Quoix, E., Lavolé, A., Bigay-Game, L., Pujol, J.-L., Langlais, A., Morin, F., Zalcman, G., & Levallet, G. (2019). Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial. Cancers, 11(12), 1835. https://doi.org/10.3390/cancers11121835